ArticleJournal of endocrinological investigation2025
Leukocytosis may be an indicator of replacement with supraphysiological dose in adrenal insufficiency: relationship with comorbidities and impaired muscle strength.
Article in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposePatients with adrenal insufficiency (AI) receiving glucocorticoid replacement therapy may occasionally be exposed to supraphysiological doses, which can lead to metabolic complications and sarcopenia. Currently, there are no laboratory markers available to predict these adverse effects. This study investigates the relationship between leukocytosis, neutrophilia, and the comorbidities associated with excess glucocorticoid exposure, and evaluates whether hemogram parameters can serve as indicators of supraphysiological glucocorticoid dosing.
methodsNinety-eight patients with primary or secondary AI receiving physiologic doses of glucocorticoid replacement were evaluated. Demographic data, laboratory findings, medications, comorbidities, and hemogram parameters were obtained from patient records. Quality of life, hand-grip strength, and body composition were assessed. Patients were examined for parameters associated with leukocytosis.
resultsThe cohort (49% female) had a median age of 41.5 years. Leukocytosis was present in 17 patients, and neutrophilia in 10 patients. Patients with leukocytosis were more likely to have hypertension, dyslipidemia, and metabolic syndrome (p = 0.001; <0.001; 0.006, respectively) and had increased BMI, waist, and hip circumferences. Hand grip strength was lower in patients with leukocytosis. A leukocyte count of > 8550/mm
conclusionLeukocytosis in patients with adrenal insufficiency on glucocorticoid replacement therapy is associated with metabolic complications and reduced muscle strength Leukocytosis may be a marker of supraphysiological GC exposure and may indicate the need for GC dose adjustment in these individuals.
Indexed as
Identifiers
40828483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.